Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles
- 31 July 1988
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 72 (2-3) , 189-197
- https://doi.org/10.1016/0021-9150(88)90080-9
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemiaAtherosclerosis, 1988
- Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipolJAMA, 1987
- Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group IIPublished by American Medical Association (AMA) ,1986
- EFFECTS OF SYNVINOLIN (MK-733) ON PLASMA LIPIDS IN FAMILIAL HYPERCHOLESTEROLAEMIAThe Lancet, 1986
- Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemiaThe American Journal of Cardiology, 1986
- Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterolJournal of Lipid Research, 1984
- Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.Journal of Clinical Investigation, 1984
- Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1984
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981
- Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesisAtherosclerosis, 1981